NEWS

• PAREXEL Launches Perceptive MyTrials® Data-Driven Monitoring To Increase Patient Safety And Reduce Clinical Trial Costs

  PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Perceptive MyTrials^® Data-Driven Monitoring solution. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials.

  On-site monitoring is a critical aspect of trial management, with the primary function of identifying and mitigating patient safety or data quality risks at investigative sites. The U.S. Food and Drug Administration (FDA) and other regulatory bodies have issued guidance to assist sponsors in developing risk-based monitoring strategies that enhance patient protection and improve trial data quality through more effective study oversight. They have encouraged greater use of centralized monitoring methods to evaluate clinical trial conduct and progress.

• inVentiv Health Acquires Equity Stake In Mytrus

  inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, recently announced that it has taken an equity stake in Mytrus, Inc., a pioneer in “virtual clinical trials” and technologies such as electronic informed consent to improve trial efficiency.

• Siren Interactive Expands Services With Online Clinical Trial Recruitment Acceleration Siren Interactive, a digital agency focused on rare disorders, has expanded its service offerings to include online clinical trial recruitment acceleration to help biopharmaceutical companies studying new medicines for rare diseases.
• NW Bio Reaches 25 Clinical Trial Sites Open And Recruiting By The End Of Q4, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax®; immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.
• Social Media Valuable Tool For Recruiting Study Participants Mayo Clinic has identified a new benefit of social media and online networking: a novel way to study rare diseases. Through patient-run websites dedicated to heart conditions and women's heart health, a team of cardiologists led by Sharonne Hayes, M.D., is reaching out to survivors of spontaneous coronary artery dissection, also known as SCAD, a poorly understood heart condition that affects just a few thousand Americans every year.
• Aeterna Zentaris Announces Completion Of Patient Recruitment For Phase 3 Trial With Perifosine In Refractory Advanced Colorectal Cancer Aeterna Zentaris Inc (the "Company") recently announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer.
• New Survey From Blue Chip Patient Recruitment Reveals Best Practices For Using Social Media In Clinical Trials Blue Chip Patient Recruitment, a division of global, full-service marketing agency Blue Chip Marketing Worldwide, has authored a white paper advising patient recruitment specialists on how to effectively implement social media into their recruitment strategies.